-
Johnson & Johnson (J&J; New Brunswick, New Jersey) said in late July that it plans to reduce its global workforce by 3% to 4%, or up to 4,820 jobs, in a restructuring that it hopes will generate about $1.3 billion to $1.6 billion in savings for 2008.
-
Researchers from the University of Washington (Seattle) and Geron (Menlo Park, California) describe a method for "coaxing" embryonic stem cells to become cardiac muscle cells, as well as a way to help those cardiac muscle cells survive and help restore heart function after transplantation into infarcted rats.
-
While Cardiovascular Device Update is obviously directed toward manufacturers of medical devices and organizations that track these companies, this sector of med-tech also should be interested in the competitive pressures of new cardiovascular drugs. This feature is focused on that interest.
-
CardioDynamics International (San Diego) reported the sale of its Vermed unit to Medical Device Partners (Regensburg, Germany), for $8 million in cash.
-
Cardiac Science, (Bothell, Washington) and US Lacrosse (USL; Baltimore), the national governing body for men's and women's lacrosse reported that they have formed analliance to increase the likelihood of surviving sudden cardiac arrest (SCA) during a lacrosse game.
-
Manufacturers of artificial hearts will take heart in the report last month by the Centers for Medicare & Medicaid Services (CMS; Atlanta) that it will re-examine its policy that denies reimbursement for the devices.
-
AngioDynamics (Queensbury, New York) reported that its board of directors has elected Vincent Bucci as its chairman.
-
Medtronic (Minneapolis) reported that it has been informed by the FDA that an advisory panel will review the premarket approval (PMA) application for its Endeavor drug-eluting coronary stent in October.
-
A new study promises to provide much more accurate data concerning complication rates for replacements and system upgrades of implantable pacemakers and defibrillators.
-
ATS Medical (Minneapolis) reported the completion of its $22 million all-cash acquisition of the surgical cryoablation business of CryoCath Technologies (Montreal).
